In an interview with Applied Clinical Trials Associate Editor Don Tracy, Sebastien Coppe, CEO, One2Treat, talks challenges ...
In this video interview, Dominique Demolle, CEO of Cognivia, talks artificial intelligence/machine learning and its potential ...
In an interview with Applied Clinical Trials Associate Editor Don Tracy, Samuel Salvaggio Senior Trial Design Lead, One2Treat ...
In this video interview, Dominique Demolle, CEO of Cognivia, highlights how patient non-adherence could increase trial ...
Machine learning can help investors dive deeper into trial data to evaluate the true potential of an asset and uncover new ...
David MacMurchy, Chief Executive Officer at Lightship, offers some insights into the company's mission toward improving equity and diversity in clinical trials.
In an interview with Applied Clinical Trials Associate Editor Don Tracy, Samuel Salvaggio, Senior Trial Design Lead, ...
Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) ...
In an interview with ACT senior editor Andy Studna at SCOPE Summit, Rajneesh Patil, vice president, digital innovation, IQVIA ...
Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...
Recent actions by the FDA and NIH in response to the current political climate have left key stakeholders in clinical trials ...
The long-held practice is effective in pinpointing the emergence of known and unknown risks to clinical development, study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback